15. A pharmaceutical composition comprising the antibody or functional fragment thereof of any one of claims 1 to 10, and optionally a pharmaceutically acceptable carrier and/or excipient.

16. Use of the antibody or functional fragment thereof as defined in any one of claims 1 to 10 in the manufacture of a medicament for treating a TNFα-related disorder or disease.